Shared by
beno
Fundamentals
Shares Outstanding: 54,815,202
Cash: $345.1m
Current liabilities: $111.36m
Current ratio: 3.75
NWC (total current assets - total current liabilities): $307m
Monthly Burn rate (net loss / months): $33.43m
Estimated current cash: $295m
Accumulated deficit: $2144m
Book value per share (Stock holder equity / Shares outstanding): $-1.6
Catalysts / News / Painting the picture
-Earnings: Q3 loss but beat on revenues
-Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
Technical Analysis
-Gap up to 11.50 on FDA priority news
-Very clean down trend all day
-Levels: 9.50, 10, 10.50
Original Plan / Strategy
First Test Short of 10.50 level
Review
Only First lot got filled, took profits at 10 cents.
Execution detail:
| Date/time | Symbol | Side | Price | Position |
|---|---|---|---|---|
| 2020-01-15 10:07:05 | CLVS | sell | $10.480 | short |
| 2020-01-15 10:08:44 | CLVS | buy | $10.380 | 0 |
Leave a comment about this trade!
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!